Stock of the Day

July 1, 2021

Maravai LifeSciences (MRVI)

$7.64
-$0.04 (-0.5%)
Market Cap: $1.99B

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Today's Trend

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is receiving a positive signal from Wall Street after Wells Fargo raised its price target to $6.50 from $5.50 and upgraded the stock to “Overweight.” The new target implies approximately 4.6% upside from the referenced share price.

  • Maravai reported second-quarter revenue of $51.44 million, exceeding analysts’ $48.67 million consensus estimate. The company also reported a quarterly loss per share of approximately $0.02, narrower than expectations of roughly $0.04-$0.05, according to the earnings coverage. Maravai LifeSciences Reports Second Quarter 2026 Financial Results
  • Wells Fargo’s higher valuation target and “Overweight” rating indicate greater confidence in Maravai’s growth outlook and provide a near-term catalyst for the shares. Wells Fargo price target report
  • Management issued fiscal 2026 revenue guidance of $205 million to $215 million, a range that broadly brackets the $210.4 million analyst consensus. The update offers limited surprise but provides visibility into the company’s expected performance. Maravai LifeSciences 2026 Q2 Results Presentation
  • Maravai remains unprofitable, with a negative net margin and negative return on equity. Continued quarterly losses could limit the stock’s upside unless revenue growth translates into improving profitability. Maravai LifeSciences Q2 earnings coverage
← Previous Stock of the DayNext Stock of the Day →